Oritavancin Monotherapy for the Treatment of vanA Vancomycin-Resistant Enterococcus faecium Infections: A Case Series from a Referral Hospital

Background: Vancomycin-resistant Enterococcus faecium (VREfm) infection treatment remains challenging. Oritavancin is active against vanA-VREfm, but clinical evidence is limited to case reports or combined treatments. This study aims to describe the characteristics and outcomes of vanA-VREfm infections treated with oritavancin monotherapy. Methods: We conducted a retrospective, single-center study at a tertiary hospital in Spain, including all adults treated with oritavancin monotherapy for vanA-VREfm infections (January 2024–December 2025). Oritavancin was administered as a 1200-mg initial dose, with weekly doses as needed. Primary outcomes were 30-day all-cause mortality and clinical failure. Secondary outcomes included 90-day mortality, relapse, microbiological recurrence, and adverse events. Susceptibility was determined by commercial broth microdilution (ComASP® Oritavancin 0.001-16, Liofilchem s.r.l.) according to CLSI criteria. Results: Ten patients received oritavancin, and seven fulfilled the inclusion criteria. The median age was 55 years (IQR 44.5–69), and the median age-adjusted Charlson comorbidity index was 7 (IQR 7–7.5). The most common source of infection was the urinary tract (n = 3). Three patients had bacteremia. All vanA-VREfm isolates were susceptible to oritavancin. Five patients had co-infection with another microorganism at the time of VREfm infection diagnosis. Three patients had a drainable focus, and all underwent source control. The median duration of oritavancin therapy was 21 days (IQR 7–42). None of the patients experienced clinical failure on day 30. The only death within 90 days was attributable to progression of underlying disease. One patient experienced an infusion-related adverse event of vomiting and shivering. No infection relapses or microbiological recurrences were observed within three months. Conclusions: In this small cohort, oritavancin monotherapy appeared to be safe and effective for treating vanA VREfm infections.

Authors

Institutions

Publication Details

Journal
Antibiotics
Published
2026-11-17
DOI
https://doi.org/10.3390/antibiotics15111146
Primary Topic
Antimicrobial Resistance in Staphylococcus
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Oritavancin Monotherapy for the Treatment of vanA Vancomycin-Resistant Enterococcus faecium Infections: A Case Series from a Referral Hospital

Adaia Albasanz‐Puig, David Campany, Ester del Barrio-Tofiño, Núria Fernández-Hidalgo et al.
3 links
Antibiotics
Antimicrobial Resistance in Staphylococcus
article

Oritavancin Monotherapy for the Treatment of vanA Vancomycin-Resistant Enterococcus faecium Infections: A Case Series from a Referral Hospital

Adaia Albasanz‐Puig, David Campany, Ester del Barrio-Tofiño, Núria Fernández-Hidalgo, Ibai Los‐Arcos, Cristina Kirkegaard-Biosca, Júlia Sellarès-Nadal, Joan Roig-Sanchis, Belén Viñado, Dolors Rodríguez-Pardo, Nieves Larrosa
article en

Abstract

Background: Vancomycin-resistant Enterococcus faecium (VREfm) infection treatment remains challenging. Oritavancin is active against vanA-VREfm, but clinical evidence is limited to case reports or combined treatments. This study aims to describe the characteristics and outcomes of vanA-VREfm infections treated with oritavancin monotherapy. Methods: We conducted a retrospective, single-center study at a tertiary hospital in Spain, including all adults treated with oritavancin monotherapy for vanA-VREfm infections (January 2024–December 2025). Oritavancin was administered as a 1200-mg initial dose, with weekly doses as needed. Primary outcomes were 30-day all-cause mortality and clinical failure. Secondary outcomes included 90-day mortality, relapse, microbiological recurrence, and adverse events. Susceptibility was determined by commercial broth microdilution (ComASP® Oritavancin 0.001-16, Liofilchem s.r.l.) according to CLSI criteria. Results: Ten patients received oritavancin, and seven fulfilled the inclusion criteria. The median age was 55 years (IQR 44.5–69), and the median age-adjusted Charlson comorbidity index was 7 (IQR 7–7.5). The most common source of infection was the urinary tract (n = 3). Three patients had bacteremia. All vanA-VREfm isolates were susceptible to oritavancin. Five patients had co-infection with another microorganism at the time of VREfm infection diagnosis. Three patients had a drainable focus, and all underwent source control. The median duration of oritavancin therapy was 21 days (IQR 7–42). None of the patients experienced clinical failure on day 30. The only death within 90 days was attributable to progression of underlying disease. One patient experienced an infusion-related adverse event of vomiting and shivering. No infection relapses or microbiological recurrences were observed within three months. Conclusions: In this small cohort, oritavancin monotherapy appeared to be safe and effective for treating vanA VREfm infections.

AntibioticsVol. 15(11)
Hebron University (PS), Universitat Autònoma de Barcelona (ES), Instituto de Salud Carlos III (ES), Vall d'Hebron Institut de Recerca (ES), Centro de Investigación Biomédica en Red (ES), Vall d'Hebron Hospital Universitari (ES), Centro de Investigación Biomédica en Red Enfermedades Infecciosas (ES)
Good health and well-being
Antimicrobial Resistance in Staphylococcus
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon